WC Rx Costs Now Vary 25-Fold by State as Trend Reversal Hits Pricing

After a decade of declining prescription drug payments per claim, the structural tailwind that WC pricing actuaries built into medical severity trend selections has reversed. The Workers Compensation Research Institute's latest 31-state prescription drug trends study, with data through Q1 2025, documents quarterly Rx payments per medical claim climbing from $51 to $63 at the median state between Q1 2022 and Q1 2025. That follows a sustained decline from $67 in early 2018. The turnaround alone would force trend re-examination. But the interstate dispersion compounds the problem: per-claim Rx costs now range from $14 in Minnesota to $353 in Louisiana, a 25-fold gap driven by regulatory divergence in formulary controls, dispensing channel restrictions, and fee schedule design. A single national Rx trend assumption is no longer defensible in loss cost filings.

The Trend Reversal: From Tailwind to Headwind

Between 2012 and 2021, declining WC prescription costs functioned as a persistent offset within blended medical severity trends. Opioid utilization reforms, formulary adoption in key states, and generic substitution mandates drove an annualized decline of approximately -2.6% in pharmacy payments per claim across NCCI states. Pricing actuaries selecting medical severity trends during this period benefited from the pharmacy component pulling the overall trend down, often by 0.3 to 0.5 percentage points relative to pure non-Rx medical severity.

That tailwind is gone. WCRI's data shows the inflection occurred around Q1 2022, when median-state quarterly Rx costs bottomed at $51 per medical claim. By Q1 2025, the median had risen to $63, a 24% increase over three years. Risk & Insurance reporting from May 2026 confirmed the pattern across most of the 31 study states. The reversal is not uniform: states with robust formulary controls and pharmacy network direction maintained flat or declining Rx trends, while permissive states saw sharp increases. That divergence is precisely what makes a blended national trend untenable for multi-state carriers.

The 25-Fold Interstate Gap

The spread between Minnesota's $14 per claim and Louisiana's $353 per claim is not random variation. It reflects structural differences in state regulatory frameworks that directly shape pharmacy cost outcomes.

States with formulary adoption, mandatory PBM contracts, and restrictions on physician dispensing or delivery pharmacy access consistently cluster at the low end. Texas, which adopted a closed formulary in 2011, has seen sustained Rx cost reductions. Georgia's April 2024 fee schedule intervention produced a dramatic and measurable shift (discussed below). Conversely, states without pharmacy network direction allow delivery pharmacies and physician dispensers to set prices at or above average wholesale price, with no copay or deductible to create demand-side cost awareness. New York's per-claim Rx payments surged 66% over the WCRI study period, reflecting the compound effect of unrestricted dispensing channels and high-cost specialty drug approvals entering the WC formulary.

For the pricing actuary, the 25-fold gap means state-specific Rx trend selections are not optional. Applying a countrywide average Rx trend to a book concentrated in high-cost states systematically understates prospective severity, while applying it to a low-cost state book overstates it.

Delivery Pharmacy: The Dominant Cost Driver

WCRI and WorkCompWire reporting from May 2026 identify delivery pharmacies as the primary mechanism through which Rx costs concentrate in high-cost states. Pennsylvania delivery pharmacies charge an average of $653 per prescription compared to $136 at retail pharmacies, a 4.8x differential. Dermatological agents, the fastest-growing therapeutic category in WC pharmacy spend, flow 70% to 95% through non-retail channels in the highest-cost states.

The delivery pharmacy model bypasses the contracted PBM networks that control costs in group health and Medicare Part D. Medications ship directly to the injured worker's home from pharmacies that operate outside standard formulary constraints, at prices set by the dispensing entity rather than negotiated by a PBM. From tracking this channel across several filing cycles, the delivery pharmacy differential is the single largest source of unexplained Rx severity variation between otherwise similar states. The pattern described in our physician dispensing markup analysis compounds the problem: physician-dispensed medications and delivery pharmacy medications together account for the bulk of the interstate cost gap.

States that have implemented pharmacy network direction rules, requiring injured workers to fill prescriptions through contracted retail pharmacies, show delivery pharmacy utilization rates below 10%. States without such rules show delivery pharmacy shares above 40% for topical medications and compounded products.

Private-Label Topicals: The Pricing Arbitrage

Within the delivery pharmacy channel, a specific category of products drives the most extreme cost outliers. Private-label topical analgesics, products manufactured under brand names not found in standard pharmaceutical references, bill at prices that bear no relationship to their ingredient costs or clinical value.

The Claims Journal's April 2026 investigation documented the specific pricing: Zylotrol at $2,425 per prescription versus a $9 OTC equivalent, Trubrexa at $2,400 versus $27 OTC, and Lidocan at $2,890 versus $90 OTC. None of these products carry FDA approval. None have demonstrated clinical superiority over generic alternatives in controlled trials. Yet they appear in WC claim files as legitimate pharmacy charges, flowing into medical severity triangles alongside clinically necessary medications. These products represent a small fraction of total prescriptions but a disproportionate share of pharmacy spend, creating a fat-tailed severity distribution that standard trend models systematically underweight.

Georgia's Fee Schedule Cap: A Natural Experiment

Georgia's April 2024 implementation of a fee schedule cap on topical medication reimbursements provides the clearest before-and-after evidence of how regulatory action bends the Rx severity curve. Within nine months of implementation, dermatological payment shares fell from 55% to 17% of total pharmacy costs in the state.

The speed and magnitude of the shift matters for pricing actuaries. A 38-percentage-point drop in the highest-cost therapeutic category's share of pharmacy spend translates directly into a measurable medical severity reduction. Georgia's experience suggests that the regulatory variable, not underlying injury mix or prescribing patterns, is the dominant driver of interstate Rx cost divergence.

For trend selection, Georgia now presents a structural break in the historical data series. The pre-April 2024 trend reflects an unrestricted market; the post-April 2024 trend reflects a capped market. Fitting a single exponential curve through both periods would understate the post-reform trend improvement. The pricing actuary must segment the data at the intervention point and fit separate trends, or apply a one-time level adjustment to normalize the pre-reform experience before projecting forward.

Bifurcating WC Medical Severity Trend Selections

Traditional NCCI medical severity trend analysis applies a single blended rate, typically derived from exponential or least-squares regression over a 10-year-plus experience window. When Rx costs were declining at -2.6% annually, this blended approach understated the adverse non-Rx severity trend while benefiting from the Rx tailwind. Now that Rx trends have reversed (+24% over three years), the blended method lags the inflection because the longer-window regression remains anchored to the declining historical period. The following four-step framework addresses this by separating the Rx and non-Rx medical severity components.

Step 1: Decompose Historical Medical Paid Losses

Split historical medical paid losses into Rx and non-Rx components using service-type classifications available in NCCI statistical plan data and state bureau filings. Most state bureaus require medical payments to be coded by service category: hospital, professional, pharmacy, and durable medical equipment. Extract the pharmacy component as a separate time series. For carriers with internal data coded at the payment level, HCPCS and NDC codes provide finer granularity, enabling sub-stratification by therapeutic class and dispensing channel.

Step 2: Fit Separate Trend Curves with Structural Break Detection

Fit exponential trend curves to each component independently. For the Rx component, the Q1 2022 inflection point violates the stationarity assumption underlying standard least-squares trend selection. Apply the Chow test or a CUSUM test to identify the structural break formally, then fit separate pre-break and post-break trend segments.

If the post-break trend window is short (three years of quarterly data through Q1 2025), the least-squares estimate will carry wide confidence intervals. The actuary should document this uncertainty per ASOP No. 25 (Credibility Procedures) and consider supplementing the short-window post-break trend with WCRI benchmark data as a Bayesian prior. For the non-Rx medical component, the longer history and absence of a comparable structural break supports a standard 10-year exponential fit.

Step 3: Apply State-Specific Credibility Weights

With a 25-fold cost range across states, state-specific Rx trend selections require careful credibility assignment. States with fee schedule caps (Georgia, Texas) have fundamentally different Rx cost trajectories than states without pharmacy network direction (New York, Pennsylvania). This parallels the credibility-weighting challenges in wage trend selection after the BLS restructured the ECI.

Apply limited fluctuation or Bühlmann credibility to blend state-level Rx trend experience with a countrywide complement. The complement pool should be stratified by regulatory regime: group fee-schedule states together, group permissive states together, and compute separate complements for each group. Blending Georgia's capped Rx trend with New York's uncapped trend produces a complement that describes neither state accurately.

For states with fewer than 500 lost-time claims per year, the state-specific Rx trend will lack statistical stability. In these cases, assign higher credibility to the regulatory-regime complement and lower credibility to state experience. The credibility threshold should be based on the coefficient of variation of the pharmacy severity per claim, not the overall medical severity, since the pharmacy component is substantially more volatile.

Step 4: Recombine into Composite Medical Severity Factor

Recombine the bifurcated trends into a composite medical severity factor using the state-specific Rx/non-Rx cost split as weights:

Composite Trend = (Rx Share × Rx Trend) + (Non-Rx Share × Non-Rx Trend)

Document the trend inflection assumption explicitly in the rate filing. ASOP No. 25 requires the actuary to disclose the rationale for trend selection, including the treatment of structural breaks, the credibility weighting methodology, and any departure from historical fitted trends. The bifurcated approach creates a clear documentation trail that regulators and peer reviewers can evaluate, rather than relying on a single number that obscures divergent cost dynamics within the medical component.

Emerging CGRP Migraine Therapy Cost Pressure

A separate development worth monitoring: CGRP inhibitor migraine therapies are entering WC pharmacy data in volume. WCRI's study shows migraine drug payment shares jumping 15 to 19 percentage points in Massachusetts, Iowa, and Kansas between 2022 and 2025. CGRP inhibitors (Aimovig, Ajovy, Emgality) carry annual costs of $6,000 to $7,000 per patient, a specialty Rx cost category that traditional WC pharmacy models do not capture. As these therapies gain adoption for post-traumatic migraine claims, they introduce a new source of Rx severity pressure independent of the topical and delivery pharmacy channel discussed above. The pricing actuary building a bifurcated Rx trend should flag CGRP therapies as a separate sub-trend within the specialty pharmacy component.

Why This Matters

The decade-long Rx cost decline created a false sense of stability in medical severity trends. Pricing actuaries who embedded that decline into blended medical trend selections are now facing an adverse trend reversal that their models are slow to capture. The 24% increase over three years, concentrated in states without effective pharmacy controls, will flow directly into higher medical severity indications once the post-2022 data fully enters the experience window.

For carriers writing WC across multiple states, the 25-fold interstate gap means that portfolio-level Rx trend assumptions mask substantial state-level variation. Bifurcating the medical severity trend into Rx and non-Rx components, with state-specific credibility weighting stratified by regulatory regime, produces more defensible indications and reduces the risk of systematic under-pricing in permissive states or over-pricing in states with effective pharmacy cost controls. The Q1 2022 inflection point is now three years old. The data is no longer ambiguous. Trend selections that ignore it will produce rate indications that are wrong in a predictable direction.